PAMIDRONATE DISODIUM FOR INJECTION 6 MG — DIN 02246598
PAMIDRONATE DISODIUM : 6 MG · FRESENIUS KABI CANADA LTD · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is PAMIDRONATE DISODIUM FOR INJECTION?
PAMIDRONATE DISODIUM FOR INJECTION 6 MG contains PAMIDRONATE DISODIUM : 6 MG. It is listed in the Health Canada Drug Product Database under DIN 02246598, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 07-Jul-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PAMIDRONATE DISODIUM FOR INJECTION used for?
Pamidronate Disodium for Injection is indicated for the treatment of tumor-induced hypercalcemia following adequate saline rehydration, conditions associated with increased osteoclast activity (predominantly lytic bone metastases and multiple myeloma), and symptomatic Paget's disease of bone.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Pamidronic Acid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Pamidronic Acid, across 23 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 3 | 3 | PAMIDRONATE DISODIUM FOR INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 3 | 3 | PAMIDRONATE DISODIUM FOR INJECTION | Sourceable in Canada |
| OMEGA LABORATORIES LIMITED | 3 | 2 | PAMIDRONATE DISODIUM OMEGA 3 MG/ML, PAMIDRONATE DISODIUM OMEGA 6 MG/ML, PAMIDRONATE DISODIUM OMEGA 9 MG/ML | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 5 | 0 | PAMIDRONATE DISODIUM FOR INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 4 | 0 | PMS-PAMIDRONATE | No marketed DIN |
| NOVARTIS PHARMACEUTICALS CANADA INC | 3 | 0 | AREDIA, AREDIA 30MG, AREDIA 90MG | No marketed DIN |
| GEIGY PHARMACEUTICALS, CIBA-GEIGY CANADA LTD. | 1 | 0 | AREDIA LIQ INJ 3MG/ML | No marketed DIN |
| VALEO PHARMA INC | 1 | 0 | VAL-PAMIDRONATE DISODIUM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 6 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Pamidronic Acid |
|---|---|
| ATC code | M05BA03 |
| AHFS class | 92:24.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02246598 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2246598 |
| Brand name | PAMIDRONATE DISODIUM FOR INJECTION |
| Generic / active ingredient | PAMIDRONATE DISODIUM : 6 MG |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Prescription |
| ATC code | M05BA03 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M05BA |
| Current status | MARKETED |
| Status date | 07-Jul-2015 |
| Original market date | 2004-03-02 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
For intravenous infusion only. Must be diluted. Single doses should not exceed 90 mg. Infusion rate must be slow. Ensure adequate hydration. Dose adjustments required for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known or suspected hypersensitivity to pamidronate disodium or other bisphosphonates; pregnancy; breast-feeding women.
Warnings and precautions
Serious: Osteonecrosis of the jaw (ONJ); renal function deterioration. Avoid bolus injection. Risk of atypical femur fractures and osteonecrosis of the external auditory canal.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 23 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| PAMIDRONATE DISODIUM FOR INJECTION | 9 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02244552 |
| PAMIDRONATE DISODIUM FOR INJECTION | 9 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02246599 |
| PAMIDRONATE DISODIUM FOR INJECTION | 3 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02246597 |
| PAMIDRONATE DISODIUM FOR INJECTION | 3 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02244550 |
| PAMIDRONATE DISODIUM FOR INJECTION | 6 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02244551 |
| PAMIDRONATE DISODIUM OMEGA 6 MG/ML | 6 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02249677 |
| PAMIDRONATE DISODIUM OMEGA 9 MG/ML | 9 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | 02249685 |
| AREDIA | 60 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02059770 |
| AREDIA 30MG | 30 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02059762 |
| AREDIA 90MG | 90 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | 02059789 |
2 · Same class — other molecules in ATC M05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Risedronic Acid | AA-RISEDRONATE DR · ACTONEL · ACTONEL DR · APO-RISEDRONATE · +15 more | 40 | 20 | Yes |
| Alendronic Acid | ACCEL-ALENDRONATE · ACH-ALENDRONATE · ACT ALENDRONATE · AG-ALENDRONATE · +31 more | 79 | 17 | Yes |
| Zoledronic Acid | ACLASTA · ACT ZOLEDRONIC ACID · ACT ZOLEDRONIC ACID CONCENTRATE · JAMP-ZOLEDRONIC ACID · +14 more | 26 | 9 | Yes |
| Pamidronic Acid | AREDIA · AREDIA 30MG · AREDIA 90MG · AREDIA LIQ INJ 3MG/ML · +6 more | 23 | 8 | Yes |
| Clodronic Acid | BONEFOS · CLASTEON · OSTAC CAP 400MG | 4 | 1 | Yes |
| Etidronic Acid | ACT ETIDRONATE · APO-ETIDRONATE · DIDRONEL INJ 50MG/ML · DIDRONEL TAB 200MG · +2 more | 9 | 0 | Not in Canada |
| Ibandronic Acid | BONDRONAT | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M05BX | Burosumab · Denosumab · Romosozumab | 9 | 8 |
| M05BB | Alendronic Acid And Cholecalciferol · Etidronic Acid And Calcium, Sequential · Risedronic Acid And Calcium, Sequential · Risedronic Acid, Calcium And Cholecalciferol, Sequential | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.